We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

129 hedge funds and large institutions have $343M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 36

37% more call options, than puts

Call options by funds: $5.57M | Put options by funds: $4.08M

29% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 24

5% more funds holding

Funds holding: 123129 (+6)

20% less capital invested

Capital invested by funds: $431M → $343M (-$88M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
129
Holders Change
+6
Holders Change %
+4.88%
% of All Funds
3.6%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
31
Increased
51
Reduced
36
Closed
24
Calls
$5.57M
Puts
$4.08M
Net Calls
+$1.5M
Net Calls Change
-$347K
Name Holding Trade Value Shares
Change
Change in
Stake
WSA
26
Wall Street Associates
California
$2.68M -$2.75M -355,600 -41%
PVI
27
Pura Vida Investments
New York
$2.12M +$1.19M +153,750 +62%
Morgan Stanley
28
Morgan Stanley
New York
$2.1M -$508K -65,666 -14%
TCIM
29
TIAA CREF Investment Management
New York
$2.08M +$406K +52,470 +15%
BIM
30
BlackRock Investment Management
Delaware
$1.86M -$35.6K -4,600 -1%
KCM
31
Kingdon Capital Management
New York
$1.8M +$2.63M +340,000 New
HCM
32
Highbridge Capital Management
New York
$1.79M +$2.62M +338,014 New
Charles Schwab
33
Charles Schwab
California
$1.64M -$82.9K -10,714 -3%
HighTower Advisors
34
HighTower Advisors
Illinois
$1.6M +$1.78M +229,538 +315%
DCM
35
DAFNA Capital Management
California
$1.57M -$163K -21,000 -7%
WRF
36
Waddell & Reed Financial
Kansas
$1.56M +$2.28M +294,300 New
Ameriprise
37
Ameriprise
Minnesota
$1.54M -$327K -42,235 -13%
Point72 Asset Management
38
Point72 Asset Management
Connecticut
$1.36M +$1.98M +256,208 New
Cambridge Investment Research Advisors
39
Cambridge Investment Research Advisors
Iowa
$1.33M -$7.74K -1,000 -0.4%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$1.29M +$1.73M +223,910 +1,112%
PA
41
Perceptive Advisors
New York
$1.2M +$1.75M +226,000 New
MCM
42
Moore Capital Management
New York
$1.19M -$774K -100,000 -31%
RFC
43
Russell Frank Company
Washington
$1.16M -$424K -54,759 -20%
CPM
44
Chesapeake Partners Management
Maryland
$1.1M +$1.34M +173,100 +495%
ACM
45
Asymmetry Capital Management
California
$1.08M +$1.57M +203,155 New
AllianceBernstein
46
AllianceBernstein
Tennessee
$1.04M +$21.1K +2,730 +1%
CI
47
Cowen Inc
New York
$1.01M -$295K -38,100 -17%
TSW
48
Thompson Siegel & Walmsley
Virginia
$1.01M -$311K -40,200 -17%
CS
49
Credit Suisse
Switzerland
$988K -$106K -13,661 -7%
GP
50
GLG Partners
United Kingdom
$984K +$1.44M +185,631 New

SGYP Hedge Fund Activity: Q3 2015 in Review

129 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2015, worth a combined $343M — down 20% from $431M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SGYP positions and 24 closed out — a net gain of 7 holders — while 51 added to existing stakes and 36 trimmed.

The largest buyer was State Street, adding an estimated $25.8M. The largest seller was York Capital Management Global Advisors, exiting entirely with an estimated $15.4M sold.

  • 129 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2015, up from 123 in Q2 2015.
  • Funds reported $343M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2015, down 20% quarter-over-quarter.
  • 31 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2015 and 24 closed out, a net change of +7 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2015 was State Street, an estimated $25.8M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2015 was York Capital Management Global Advisors, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2015.